Allstate corp exec Gupta sells $301k in stock

Allstate saw a planned insider sale on Nov. 14 when President of Enterprise Solutions Suren Gupta sold 1,400 shares for roughly $301,030 while simultaneously exercising options to buy 1,400 shares at $62.32 (total exercise cost ~$87,248); the trades were executed under a pre-arranged Rule 10b5-1 plan as the stock traded near its 52-week high (~$215.70) and was quoted at $209.21. The company reported a substantial Q3 beat—EPS $11.17 versus $7.43 expected and revenue $17.3 billion versus $15.69 billion—which prompted analysts at Keefe, Bruyette & Woods and BMO to raise price targets to $250 and $244 respectively while maintaining Outperform ratings. With Allstate trading at a modest P/E of 6.77 and analysts lifting forecasts for policy growth and earnings, the data point to renewed upside potential for the insurer, while the insider sale appears procedural rather than a signal of deteriorating fundamentals.

Analysis

Suren Gupta, Allstate's President of Enterprise Solutions, sold 1,400 shares on November 14, 2025 at $215.00–$215.07 for roughly $301,030 and simultaneously exercised options to acquire 1,400 shares at $62.32 for about $87,248; the transactions were executed under a pre-arranged Rule 10b5-1 plan adopted June 9, 2025. At the time Allstate traded near its 52-week high of $215.70 with the quoted price at $209.21, and Gupta now directly owns 100,646 shares with additional small holdings through a 401(k) and VVG Holdings LLC.

Allstate reported a materially positive third-quarter beat with EPS of $11.17 versus consensus $7.43 and revenue of $17.3 billion versus $15.69 billion, prompting Keefe, Bruyette & Woods to raise its price target to $250 and BMO Capital to lift its target to $244 while both retained Outperform ratings. InvestingPro highlights a modest P/E of 6.77, suggesting the market may be underpricing the company given the earnings surprise and analyst upward revisions tied to monthly auto organic growth assumptions.

The insider sale appears procedural—given the 10b5-1 plan and concurrent option exercise—so it does not, on its own, signal deteriorating fundamentals; the primary stock drivers from the article are the earnings beat, revenue outperformance, and analyst re-ratings. Sentiment signals are moderately positive, which supports a potential re-rating, but investors should monitor execution on auto policies in force, reserve development, and any future guidance revisions since the article provides no forward-looking detail beyond the quarter.

Key Decisions for Investors

• Consider initiating or modestly increasing exposure to ALL given the Q3 EPS beat ($11.17 vs $7.43), revenue outperformance ($17.3B vs $15.69B), analyst target upgrades to $244–$250, and a reported P/E of 6.77
• Treat the Nov. 14 insider sale as procedural because it occurred under a pre-arranged 10b5-1 plan and involved option exercise; prioritize monitoring monthly auto organic growth metrics and upcoming reserve commentary for confirmation of sustained improvement
• Size positions prudently and implement clear risk controls (stops or hedges) because the article’s positives could be offset by adverse loss development or macro shocks that are not addressed in the report